Edegem

• A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX versus mFOLFIRINOX Alone in Patients wit … Recruiting
  2022-502404-73-00 4 2024-06-03 Pancreatic ductal adenocarcinoma
• A Phase 3 study of Dostarlimab as Sequential Therapy after Chemoradiation compared to placebo in adult participants with Locally Advanced Un … Recruiting
  2023-508613-17-00 5 2024-05-29 Neoplasms, Head and Neck
• Phase 1, First-in-Human Study to Assess the Safety, Tolerability and Anti-tumor Activity of CDR404 in HLA-A*02:01 Participants with MAGE-A4 … Recruiting
  2023-508808-38-00 1 2024-05-29 Solid tumors
• A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezom … Recruiting
  2023-507632-20-00 5 2024-05-01 Multiple Myeloma
• A Study to Investigate the Pharmacokinetics (PK) and Safety of Risdiplam in Infants with Spinal Muscular Atrophy Recruiting
  2023-505602-42-00 4 2024-04-30 Spinal Muscular Atrophy (SMA)
• A Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician’s Ch … Recruiting
  2023-505660-11-00 5 2024-04-24 Cholangiocarcinoma (LTT, 26.0)
• Study to learn about the safety of fazirsiran and if it can help people with alpha-1 antitrypsin liver disease with mild liver scarring (fib … Recruiting
  2023-504198-19-00 5 2024-04-18 Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
• RADAR: A randomised phase III trial with a PET response adapted design comparing ABVD +/- ISRT with A2VD +/- ISRT in patients with previousl … Recruiting
  2022-500031-37-00 5 2024-04-08 ​ stage IA/IIA Hodgkin lymphoma
• A multicenter uncontrolled, open label, prospective non-comparative single arm phase II study with bicalutamide (an antiandrogen) in combina … Recruiting
  2022-502272-23-00 4 2024-04-08 Locally advanced unresectable or metastatic androgen receptor positive
• STUDY OF OP-1250 ADMINSTERED AS MONOTHERAPY AND COMPARED TO STANDARD OF CARE FOR THE TREATMENT OF ER+, HER2– ADVANCED OR METASTATIC BREAST C … Recruiting
  2023-505871-63-00 5 2024-04-08 ER+, HER2- metastatic breast cancer following endocrine and CDK 4/6 in
• Phase 3 study of adjuvant V940 and Pembrolizumab in resected Stage II, IIIA, IIIB NSCLC Recruiting
  2023-504923-20-00 5 2024-04-04 Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer
• An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting
  2023-504031-41-00 5 2024-03-25 ER+/HER2- Early Breast Cancer
• A Long-Term Study of Elafibranor in Adult Participants with Primary Biliary Cholangitis (ELFIDENCE) Recruiting
  2023-505251-43-00 5 2024-02-28 Primary Biliary Cholangitis
• Study Comparing the Efficacy and Safety of the Combination of Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib … Recruiting
  2023-503708-10-00 5 2024-02-20 Locally advanced or metastatic breast cancer
• Efficacy and safety of conventional neoadjuvant therapy versus total neoadjuvant therapy in older patients with locally advanced rectal canc … Recruiting
  2023-506703-26-00 5 2024-02-07 locally advanced rectal cancer
• COLchicine in BElgium in patients with coronary artery disease after Percutaneous Coronary Intervention Recruiting
  2023-505028-74-00 5 2024-01-29 Coronary artery disease
• Tapering of Rituximab Based on Interval Prolongation Compared to Disease Activity-Guided Dose Reduction in Patients with Rheumatoid Arthriti … Recruiting
  2023-506638-59-01 6 2024-01-09 Rheumatoid arthritis
• Personalized, CT-guided antithrombotic therapy versus lifelong single antiplatelet therapy to reduce thromboembolic and bleeding events in n … Recruiting
  2023-504637-42-01 6 2023-12-21 aortic valve stenosis
• An Extension study of the Long-Term Safety, Tolerability, and Efficacy of DNL310 in Participants With Mucopolysaccharidosis Type II (MPS II) … Recruiting
  2023-503837-23-00 5 2023-12-12 Mucopolysaccharidosis Type II [MPS II]
• 177Lu-edotreotide compared to everolimus in neuroendocrine tumors of the lung and thymus Recruiting
  2022-502154-13-00 5 2023-10-27 Patients with well to moderately differentiated neuroendocrine tumors
• Semaglutide for the treatment of glucose intolerance in women with prior gestational diabetes Recruiting
  2022-502082-22-00 11 2023-09-14 prediabetes
• A multi-center randomized, double blinded phase IIb trial evaluating oral pooled fecal microbiotherapy MaaT033 to prevent allogeneic hematop … Recruiting
  2022-501831-18-00 4 2023-09-13 Patients with hematologic malignancies and undergoing allogenic hemato
• A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination with Checkpoint Inhibitor i … Recruiting
  2023-504709-35-00 1 2023-08-16 Locally advanced or metastatic solid tumors
• Continuing Somatostatin Analogues Upon progression in Neuroendocrine tumour pAtients (SAUNA trial) Recruiting
  2022-502703-30-00 6 2023-06-28 neuroendocrine tumours

Showing 193–216 of 583 trials